Programme Thesis
The DayOne Accelerator is a 3-month hybrid, equity-free, fee-free startup acceleration programme based in Basel, Switzerland, run by Basel Area Business & Innovation. It exists to bridge the gap between early-stage healthtech/techbio ventures and the pharmaceutical R&D industry — not to fund research, but to help founded startups with prototypes refine their pharma-specific value proposition, access Novartis/Roche/Lonza executives as mentors, and land real partnership conversations. Up to 3 of the 15 selected cohort companies can also receive post-accelerator CHF 50K non-dilutive funding + CHF 50K in services + 12 months desk space (DayOne NEXT).
Selection Criteria
• Stage: Pre-Seed to Series A; less than US$10M dilutive funding raised to date
• Must be a startup or incorporated venture — not an individual researcher or academic project
• Core criterion: solution must directly enable or accelerate a step inside pharma R&D workflows (AI drug discovery, digital/imaging biomarkers, companion diagnostics, clinical trial optimisation, patient stratification, decentralised trials, R&D data/analytics, lab automation)
• Explicit out-of-scope: basic/academic research with no commercial product, therapeutic molecule development, consumer health apps, hospital-ops software, medical device hardware without pharma R&D angle
• Must have a prototype or product deliverable to pharma within 12–18 months
• International teams from any country eligible
• Selection by expert jury including pharma executives (Roche, Novartis, J&J, Debiopharm), VCs (Laconia, Nina Capital, Kurma), and industry advisors — jury weights pharma-specific value proposition clarity, market access readiness, and team credibility
• Competitive: 2025 cohort selected 15 from ~200 applications across 40+ countries
Past Winners / Cohort Profiles
The 2025 cohort (15 startups) skewed heavily toward AI/software companies enabling clinical trials and drug discovery: OmniScience (AI control tower for clinical trials), Harmonic Discovery (AI multi-target drug selectivity platform), Navis Bio (AI competitive intelligence for biopharma), Lemna Bio (structure-first AI for molecular probes), Octozi (AI data-cleaning for clinical trials), Grove AI (AI agents for trial operations), Menken Trials (real-time compliance intelligence), StratifAI (multimodal predictive biomarkers), EVIIVE (EV-based liquid biopsy), Parithera (single-cell RNA-seq from blood), C. Light Technologies (retinal eye-tracking AI), ZuriEV (brain tumor liquid biopsy), Areltys (digital oncology access), Nanolynx Biologics (nanobody-drug conjugates), Virtuosis AI (vocal biomarker diagnostics). Pattern: digital-first, AI-heavy, with a clear pharma customer (not patients) — primarily clinical-stage intelligence tools, multi-omic platforms, and precision medicine analytics. Prior cohorts include Senseera, Oncoustics, Theremia, Risklick — all founded startups with distinct pharma-facing products.
Ideal Candidate Fingerprint
The platonic ideal DayOne applicant is a 1–3 person founding team with a working software/AI prototype that solves a measurable pain point inside pharma R&D (e.g. trial operations, biomarker discovery, data cleaning, drug-target modelling), can articulate a clear B2B pharma customer and willingness-to-pay, and is ready for in-person Basel networking within 6 months. They are legally incorporated, investor-ready, and seeking pharma partnerships rather than grant funding per se. A strong LMIC or international angle is a mild differentiator but is not primary; pharma R&D fit dominates.
Recommended Framing
Eniola should apply not as a researcher but as the founder of TOPOLOGIX — her TDA-based drug-protein interaction platform with persistent homology, bipartite simplicial complexes, and hERG cardiotoxicity MVP — framing it as an early-stage computational TechBio startup targeting pharma R&D safety screening and target identification workflows, exactly the category DayOne funds. The CCT model and IMPRINT add depth (computational pharmacology expertise, addiction-liability screening) but TOPOLOGIX is the commercial hook: it directly addresses a Roche/Novartis pain point (hERG/cardiotoxicity safety prediction and multi-target interaction modelling) with a working prototype, published methodology, and collaboration with Berridge/Gershman/Daw as scientific validators. The pitch deck and business plan should position TOPOLOGIX as a drug safety/discovery intelligence tool that pharma can license or co-develop, not as an academic platform — DayOne's jury responds to 'our software shortens your preclinical attrition' not 'we have a novel mathematical model'.
Watch Out
1. DEADLINE ALREADY CLOSED: The 2026 application window closed May 31, 2026; today is July 11, 2026. The next opportunity is the 2027 cohort (applications expected to open March 2027). Applying now is not possible — this opportunity should be flagged for the 2027 calendar.
2. STARTUP vs RESEARCHER mismatch: DayOne is a startup accelerator, not a researcher fellowship. Eniola's current identity is 'independent researcher' with no registered startup entity. She must incorporate TOPOLOGIX (or IMPRINT) as a company before applying — applications from unincorporated individuals are out of scope.
3. CCT model is explicitly out of scope: basic/academic research with no commercial product is excluded. The CCT preprints, Bayesian models, and ODE simulations are impressive academically but cannot anchor the DayOne application — only TOPOLOGIX or IMPRINT can.
4. Pharma R&D value proposition needs sharpening: TOPOLOGIX must be articulated as a tool pharma buys or licenses, with a named workflow, a named buyer persona (e.g. computational chemist at Novartis Global Drug Discovery), and a quantified benefit (e.g. '40% faster hERG liability triage').
5. Competition is intense: 200 applicants from 40+ countries; the jury is pharma-industry-heavy and evaluates startup maturity, not academic merit.